Stock Analysis

Earnings Miss: Elekta AB (publ) Missed EPS By 5.4% And Analysts Are Revising Their Forecasts

Last week, you might have seen that Elekta AB (publ) (STO:EKTA B) released its quarterly result to the market. The early response was not positive, with shares down 9.9% to kr60.30 in the past week. Revenues of kr4.7b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at kr0.89, missing estimates by 5.4%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Elekta

earnings-and-revenue-growth
OM:EKTA B Earnings and Revenue Growth February 26th 2025

Taking into account the latest results, the most recent consensus for Elekta from 13 analysts is for revenues of kr19.6b in 2026. If met, it would imply a decent 9.7% increase on its revenue over the past 12 months. Per-share earnings are expected to shoot up 60% to kr4.35. Before this earnings report, the analysts had been forecasting revenues of kr19.9b and earnings per share (EPS) of kr4.69 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

The consensus price target held steady at kr70.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Elekta analyst has a price target of kr127 per share, while the most pessimistic values it at kr51.50. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Elekta's rate of growth is expected to accelerate meaningfully, with the forecast 7.7% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 6.3% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 16% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, Elekta is expected to grow slower than the wider industry.

Advertisement

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Elekta. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Elekta's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Elekta analysts - going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Elekta that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Elekta might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:EKTA B

Elekta

A medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Reasonable growth potential with adequate balance sheet and pays a dividend.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

BO
MU logo
BonSquid88 on Micron Technology ·

Micron Technology will experience a robust 16.5% revenue growth

Fair Value:US$40021.1% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
AMZN logo
MarketMuse on Amazon.com ·

Amazon will rebound as AI investments start paying off by late 2026

Fair Value:US$45049.7% undervalued
45 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
HVN logo
Robbo on Harvey Norman Holdings ·

Inside Harvey Norman: Asset-Heavy Retail in an Online World

Fair Value:AU$5.8419.5% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1013 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative